Early Transplantation After Pretransplant Reduction of TP53-Altered Clones and Prolonged Dose-Adjusted Azacitidine Maintenance: A Three-Case Series [0.03%]
移植前减少TP53变异克隆的移植术及调整剂量阿扎胞苷维持治疗:3例报道
Fuyuki Yamagata,Kyoko Yoshihara,Yasuhito Nannya et al.
Fuyuki Yamagata et al.
TP53-altered myeloid neoplasms are associated with an extremely high risk of relapse even after allogeneic hematopoietic cell transplantation (allo-HCT), and the optimal pretransplant and posttransplant strategies remain undefined. We repor...
Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Mantle Cell Lymphoma: Real-World Outcomes, Late Relapse Patterns, and Clinical Utility in the Chimeric Antigen Receptor T-Cell Era [0.03%]
异基因造血细胞移植治疗复发或难治性套细胞淋巴瘤:真实世界的结果、晚期复发模式及CAR-T细胞时代临床应用价值的评估
Enver Aydilek,Paolo Mazzeo,Justin Hasenkamp et al.
Enver Aydilek et al.
Background: Allogeneic hematopoietic cell transplantation (alloHCT) remains a curative option for relapsed or refractory (r/r) mantle cell lymphoma (MCL), although its role has shifted in the era of Bruton tyrosine kinase...
Biological Drivers of IMiD-Induced Peripheral Neuropathy in Multiple Myeloma [0.03%]
免疫调节剂诱导的多发性骨髓瘤外周神经病变的发病机制研究进展
Sina A Beer,Richard Houlston,Martin F Kaiser
Sina A Beer
The introduction of immunomodulatory drugs (IMiDs), such as thalidomide, lenalidomide and pomalidomide, have led to significant improvements in multiple myeloma (MM) treatment. Many patients now live 10 years or longer with their disease, m...
Validation of Gazelle Microchip Electrophoresis for Premarital Hemoglobinopathy Screening in Türkiye [0.03%]
土耳其婚前血红蛋白病筛查中羚羊微芯片毛细管电泳法的验证研究
Duran Canatan,Serpil Delibaş,Emel Altunsoy et al.
Duran Canatan et al.
Introduction: Hemoglobinopathies, the most prevalent recessive monogenic disorders globally, encompass thalassemia syndromes and structural hemoglobin variants, affecting approximately 5% of the world's population as carr...
Thrombotic Events in Patients With Paroxysmal Nocturnal Haemoglobinuria Using Eculizumab: A Post-Marketing Surveillance Sub-Analysis [0.03%]
艾库珠单抗治疗阵发性睡眠性血红蛋白尿症患者的血栓事件:一项上市后监测的子分析研究
Takayuki Ikezoe,Tatsuya Kawaguchi,Hideo Hayashi et al.
Takayuki Ikezoe et al.
Background: Thrombotic events (TEs) account for approximately 40%-67% of deaths in untreated paroxysmal nocturnal haemoglobinuria (PNH). C5 inhibitor treatment (e.g., eculizumab and ravulizumab) greatly reduces the incide...
RASGRP1 Deficiency Manifesting as Severe Vasculopathy and Fatal Autoimmune Hemolytic Anemia [0.03%]
RASGRP1缺乏导致的严重血管病和致命自身免疫性溶血贫血
Kosar Asna Ashari,Bahareh Yaghmaie,Neda Pak et al.
Kosar Asna Ashari et al.
Background: RASGRP1 deficiency is a rare inborn error of immunity characterized by immunodeficiency, autoimmunity, and lymphoproliferation. Results: ...
Transcranial Doppler Ultrasound Velocity Measurements in Children With Sickle Cell Disease in Kenya [0.03%]
肯尼亚镰状细胞病儿童经颅多普勒超声速度检测结果
Catherine Mwalimu,Oscar Odhiambo,Elaine Mashisia et al.
Catherine Mwalimu et al.
Background: Sickle cell disease (SCD) is the most common inherited haemoglobinopathy and poses a high public health burden in Sub-Saharan Africa. Children with sickle cell anaemia are at a highrisk of ischemic stroke, and...
Development of a Clinical Severity Score for Indian Sickle Cell Anaemia Patients [0.03%]
印度镰状细胞贫血患者临床严重程度评分的制定
Suraj S Nongmaithem,Amitabh Biswas,Swaroop Iyer et al.
Suraj S Nongmaithem et al.
Background: Sickle cell anaemia (SCA) is a monogenic disorder but shows variable disease severity. We evaluated the utility of paediatric severity scores (PSS) in Indian patients and developed two modified scores: Indian ...
Prevalence of Low Bone Mineral Density Increases With Age in Sickle Cell Disease [0.03%]
镰状细胞病患者骨密度偏低的发生率随年龄增长而升高
Jahnavi Gollamudi,Chengzhou Wu,Guolian Kang et al.
Jahnavi Gollamudi et al.
Introduction: Skeletal complications are common in sickle cell disease (SCD). We previously showed that the prevalence of low areal bone mineral density (aBMD) increased with age in a pediatric SCD cohort, even after adju...
Triplet or Quadruplet Regimen Utilization and Overall Survival in Patients Diagnosed With Multiple Myeloma Between 2017 and 2023 [0.03%]
2017年至2023年期间确诊的多发性骨髓瘤患者的三联或四联方案使用与总生存率的关系
Emily R Wesley,Faiz Anwer,Michael B Rothberg et al.
Emily R Wesley et al.
Introduction: Multiple myeloma treatment has rapidly evolved, but little is known about the uptake of guideline-recommended triplet or quadruplet therapy in clinical practice. ...